Motixafortide

(Aphexda®)

Motixafortide

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormInjection (subcutaneous; 62 mg as a lyophilized powder in a single-dose vial for reconstitution)
Drug ClassHematopoietic stem cell mobilizers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Motixafortide (Aphexda) is indicated for use in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. The GENESIS study demonstrated a significant superiority of Aphexda + G-CSF over placebo + G-CSF, indicating a marked improvement in stem cell mobilization efficiency.
  • Two randomized controlled trial studies were reviewed, providing comprehensive insights into the safety and effectiveness of Aphexda, especially when compared to the current standard treatment for mobilizing hematopoietic stem cells.
  • Both studies focused on adult patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. There was no mention of subgroup analyses within these patient populations based on age, disease stage, or previous treatment history.
  • In terms of the safety profile, Aphexda demonstrated manageable adverse events primarily localized at the injection site such as pain, erythema, and pruritus. This suggests that it adds a tolerable safety profile when used alongside G-CSF compared to its standalone use, known for causing bone pain and leukocytosis.
  • Compared directly against placebo + G-CSF during trials, Aphexda combined with G-CSF showed significantly improved efficacy in mobilizing a sufficient number of HSPCs required for a successful transplantation procedure among MM patients.
  • While there is an implicit comparison suggesting superior performance by combining Aphexda + G-GSF than using only the standard treatment alone (given the placebo comparison), detailed comparative data against other CXCR4 inhibitors or other agents involved in similar procedures were not provided explicitly within the studies reviewed.

Product Monograph / Prescribing Information

Document TitleYearSource
Aphexda (motixafortide) Prescribing Information.2023BioLineRx Ltd., Modiā€™in, Israel

Randomized Controlled Trials


Sex Distribution:

F:36%
M:64%
134Subjects

Year:

2019

Source:Future Oncology